問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

List

2449Cases

2014-03-01 - 2019-01-31

Phase III

A phase III, placebo-controlled, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of K-333 (peretinoin) in patients with complete cure of hepatocellular carcinoma in Asia

  • Condition/Disease

    hepatocellular carcinoma

  • Test Drug

    K-333

Participate Sites
17Sites

Terminated16Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

2021-05-31 - 2027-12-31

Phase II/III

AN ADAPTIVE PHASE II/III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TWO-PART, DOSE-FINDING, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF NABEN® (SODIUM BENZOATE), A D-AMINO ACID OXIDASE INHIBITOR, AS AN ADD-ON THERAPY WITH CLOZAPINE, FOR RESIDUAL SYMPTOMS OF REFRACTORY SCHIZOPHRENIA IN ADULTS

  • Condition/Disease

    Residual Symptoms of Refractory Schizophrenia in Adults

  • Test Drug

    NaBenR

Participate Sites
5Sites

Recruiting5Sites

2021-05-31 - 2023-11-29

Phase II/III

AN ADAPTIVE PHASE II/III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TWO-PART, DOSE-FINDING, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF NABEN® (SODIUM BENZOATE), A D-AMINO ACID OXIDASE INHIBITOR, AS AN ADD-ON THERAPY WITH CLOZAPINE, FOR RESIDUAL SYMPTOMS OF REFRACTORY SCHIZOPHRENIA IN ADULTS

  • Condition/Disease

    Residual Symptoms of Refractory Schizophrenia in Adults

  • Test Drug

    NaBenR

Participate Sites
6Sites

Recruiting6Sites

2015-03-01 - 2016-10-26

Phase II

A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Treatment naïve East Asian Subjects With Chronic Hepatitis C Virus Genotype 1b Infection.

  • Condition/Disease

    Hepatitis C

  • Test Drug

    TG-2349

Participate Sites
9Sites

Terminated9Sites

鄭斌男
National Taiwan University Hospital

Division of General Internal Medicine

2010-03-06 - 2011-09-27

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-06-01 - 2009-01-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2007-11-01 - 2009-10-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Study ended1Sites

2020-08-01 - 2021-08-19

Phase III

A Phase III, Prospective, Multi-center, Double-blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of Pitavastatin 2 mg/ Ezetimibe 10 mg with Pitavastatin and Ezetimibe in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia

  • Condition/Disease

    Primary Hypercholesterolemia/Mixed Dyslipidemias

  • Test Drug

    1PC111

Participate Sites
23Sites

Not yet recruiting4Sites

Recruiting19Sites

2012-07-01 - 2019-08-31

Phase II/III

A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects with Pulmonary Tuberculosis

  • Condition/Disease

    A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects with Pulmonary Tuberculosis

  • Test Drug

    Isoniazid tablet formulated with excipient HUEXC030

Participate Sites
13Sites

Terminated13Sites

2015-10-01 - 2019-08-31

Phase III

An Extension Study to Evaluate the Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents with ADHD

  • Condition/Disease

    Attention Deficit Hyperactivity Disorder (ADHD)

  • Test Drug

    ORADUR®-Methylphenidate

Participate Sites
3Sites

Terminated3Sites

1 237 238 239 240 241 245
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB